Journal article icon

Journal article

Investment in antimalarial drug development is bearing fruit

Abstract:
Front-line antimalarial drugs (the artemisinin-based combination therapies) are failing in southeast Asia, making the need for novel antimalarials more pressing than ever. In The Lancet Infectious Diseases, two studies of DSM265, a plasmodium dihydroorotate dehydrogenase inhibitor, are reported. This novel antimalarial, discovered by a team at the University of Texas Southwestern, is in phase 2 clinical development for the prophylaxis and treatment of malaria.
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.1016/S1473-3099(17)30172-X

Authors


More by this author
Institution:
University of Oxford
Division:
MSD
Department:
NDM
Sub department:
Tropical Medicine
Role:
Author
Publisher:
Elsevier Publisher's website
Journal:
Lancet Infectious Diseases Journal website
Volume:
17
Issue:
6
Pages:
568–570
Publication date:
2017-03-01
Acceptance date:
2017-03-07
DOI:
EISSN:
1474-4457
ISSN:
1473-3099
Source identifiers:
698509
Pubs id:
pubs:698509
UUID:
uuid:1b4e3337-23f3-4fec-acd1-a54d73711ca2
Local pid:
pubs:698509
Deposit date:
2017-06-17

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP